01 May 2018

Hong Kong Launches New Rules on Biotech Listings

Our Client Briefing on Biotech Listings focusses on the regime for pre-revenue biotech companies

The Stock Exchange of Hong Kong Limited (the Exchange) has concluded its consultation on a listing regime for emerging and innovative companies and finalised the related Hong Kong Listing Rules and guidance letters.

From 30 April 2018, biotech companies that are pre-revenue are permitted to list under a new chapter (the Biotech Chapter) in the Main Board Listing Rules (the Listing Rules).


Hong Kong Launches New Rules on Biotech Listings

 

This material is provided for general information only. It does not constitute legal or other professional advice.

Practices Capital Markets
Contact Information
Benita Yu
Partner at Slaughter and May
London
John Moore
Partner at Slaughter and May
London
Peter Brien
Partner at Slaughter and May
London